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Abstract
Context—Health risks associated with subclinical hypothyroidism in older adults are unclear.
Objective—To compare the functional mobility of seventy-year-olds by thyroid function
categorized by thyroid stimulating hormone (TSH) level as euthyroid (0.4 mU/L< TSH <4.5 mU/
L) or having mild (4.5 mU/L≥ TSH <7.0 mU/L) or moderate subclinical hypothyroidism (7.0 mU/
L≤ TSH ≤20.0 mU/L with normal FT4) cross-sectionally and over two years.
Design, Setting, and Participants—2,290 community residents participating in the Year 2
clinic visit (July 1998-June 1999) of the Health, Aging and Body Composition study with
measured TSH, capacity to walk 20 meters unaided and not taking thyroid medication or having
TSH levels consistent with hyper- or hypothyroidism.
Main Outcome Measures—Self-reported and performance-based measures of mobility (usual
and rapid gait speed and endurance walking ability) assessed at study baseline (Year 2) and two
years later.
Results—In age- and sex-adjusted analyses the mild subclinical hypothyroid group demonstrated
better mobility – faster usual and rapid gait speed (1.20 vs. 1.15 m/s and 1.65 vs. 1.56 m/s; p<.
001) and higher percent with good cardiorespiratory fitness and reported walking ease (39.2 vs.
28.0 and 44.7 vs. 36.5; p<.001). After two years, persons with mild subclinical hypothyroidism
experienced similar decline as the euthyroid, but maintained their mobility advantage. Persons
with moderate subclinical hypothyroidism had similar mobility and decline as the euthyroid group.
Conclusions—Generally well-functioning seventy-year-olds with subclinical hypothyroidism
do not demonstrate increased risk of mobility problems and those with mild elevations in TSH
show a slight functional advantage.
INTRODUCTION
Prevalence of subclinical hypothyroidism, defined as elevated thyroid stimulating hormone
(TSH) with free thyroxine (FT4) in the normal range, increases with age affecting about 6%
of persons aged 70 to 79 years and 10% of those aged 80 or older.1 Although a chief concern
with subclinical hypothyroidism has been risk of progression to overt hypothyroid disease,2,
3 elevated lipid levels,4–6 increased risk of cognitive impairment7 and cardio-vascular
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conditions, including myocardial infarction8 and mortality,9–11 research findings have not
consistently supported these concerns,12–14 particularly in elderly individuals15–17 and those
with only mild elevations of TSH.9, 14 In fact, findings in a cohort of persons aged 85 years
suggest that subclinical hypothyroidism may be associated with a prolonged survival.18
Additionally, an analysis of age-specific distributions of serum thyrotropin and antithyroid
antibodies in the U.S. population indicates a shift toward higher concentrations of TSH with
increasing age1 suggesting a resultant upward shift in normal concentrations.
In this study we sought to evaluate the potential meaning and importance of various levels of
TSH traditionally defined as in the normal to subclinical hypothyroidism range by
examining associations with several dimensions of walking ability concurrently and
prospectively over two years. We focused on functional mobility because it is widely
considered a global marker of current health status and risk of future negative health events
in older adults.19, 20.
The few studies of older adults that have distinguished levels of subclinical hypothyroidism
have generally found the mild group to exhibit the most favorable profile.18 On the basis of
studies restricted to older adults,16 we hypothesized that persons with moderate subclinical
hypothyroidism would exhibit similar mobility status and rates of mobility decline as
persons with traditionally defined normal thyroid function and those with mild subclinical
hypothyroidism would demonstrate a slightly more favorable mobility profile and less
decline.
METHODS
Study Population
The study population derives from the Health, Aging and Body Composition (Health ABC)
study, a population-based biracial cohort study of 3075 men and women residing in the
communities of Memphis, TN or Pittsburgh, PA aged 70 to 79 years at the baseline
enrollment period (Year 1) extending from April 1997 through June 1998. Potential
participants were identified from a random sample of white and all age-eligible black
Medicare beneficiaries living in designated zip code areas surrounding the study sites who
were screened to select well-functioning individuals – those reporting no difficulty walking
one quarter mile, climbing one flight of stairs or performing basic activities of daily living.
These individuals are representative of the approximately fifty percent of U.S. residents
aged 70 to 79 years with no apparent mobility limitations. Persons participating in
behavioral intervention studies, planning to leave the area within three years or having a
diagnosis of a life-threatening cancer were excluded.
Participants eligible for the current study had a valid fasting blood draw and measurement of
TSH level in Year 2 (n=2800). Persons taking either thyroid antagonist (n=2) or exogenous
thyroid hormone (n=276) medications and those with evidence of overt hypothyroidism
(TSH >20 mU/L; n=13 or TSH ≥7.0 mU/L and a thyroxine <0.8 6 dg/dL; n=7) or low TSH
consistent with hyperthyroidism (TSH <0.45 mU/L; n=51) were excluded. Given the interest
in mobility parameters, persons unable to walk 20 meters without a walking aid (n=88) or
who had a home visit (n=73) and therefore were not administered the 20-m walk test were
also excluded, yielding an analysis cohort of 2290. This group of 161 excluded individuals
did not differ with respect to thyroid function from those included in the study (p=.70).
Measures
Thyroid Function—Thyrotropin levels were measured at a central laboratory (University
of Vermont) in all participants who had a clinic or home visit and agreed to and had a blood
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draw (n=2,800) by immunoassay (ACS; Chiron Diagnostics Corp, Emeryville, CA). The
normal range provided by the manufacturer for this assay is 0.35 to 5.5 mU/L, with a lower
limit of detection of 0.03 mU/L and a coefficient of variation of 3.6% at a level of 1.26 mU/
L. FT4 was assessed by competitive immunoassay (ACS; Diagnostics Corp, Emeryville,
CA) on all participants with a TSH level ≤0.1 mU/L or ≥7.0 mU/L. The normal range
provided by the manufacturer is 0.8 to 1.8 ng/dL. For the main analyses, three groups were
distinguished – euthyroid (0.4 mU/L< TSH <4.5 mU/L), mild subclinical hypothyroid (4.5
mU/L≥ TSH <7.0 mU/L) and moderate subclinical hypothyroid (7.0 mU/L≤ TSH ≤20.0
mU/L with normal FT4), based on the definitions used by the U.S. Preventive Services Task
Force.14 We selected a TSH level of 7.0 mU/L to distinguish mild from moderate subclinical
hypothyroidism since it represents the 97.5 centile in a representative U.S. population aged
70 and older free of thyroid disease.1 As a secondary analysis to better understand the
relationship between mobility and thyroid function over a continuum of TSH, we
constructed a nine level variable in which the first 7 seven levels were defined in 1.0 mU/L
increments and the last two encompass moderate subclinical hypothyroidism subdivided at
10.0 mU/L.
Mobility Parameters—The mobility parameters include both self-report and
performance-based measures designed to tap the full continuum of mobility from perceived
difficulty and ease walking and basic to advanced walking performance.
Reported mobility capacities and limitations were determined from responses to a series of
questions beginning with, “Because of a health or physical problem, do you have any
difficulty walking a quarter of a mile that is about 2 or 3 blocks, without stopping?” Those
reporting difficulty were asked whether they had a little, some or a lot of difficulty or were
unable to walk. Persons expressing no difficulty were asked how easy it is for them to walk
a quarter of a mile – very, somewhat, or not so easy - followed by whether they have any
difficulty walking one mile and the ease of walking one mile if no difficulty was reported.21
Responses to these questions were combined to create a walking ability index ranging from
0 to 9, where 0 represents unable to walk ¼ mile and 9 indicates walking one mile is very
easy. We also examined separately prevalence of walking limitation (any difficulty walking
¼ mile) and good walking capability (reporting walking one mile is very easy).
Performance-based evaluations include usual and rapid gait speed, measures of basic and
reserve capacity, assessed over a 20 meter course. Participants were asked first to walk at
their “usual walking pace” and then “as fast as [they] can” for the return trip. Total time
recorded to the hundredth of a second was divided into 20 to obtain respectively usual and
rapid gait speed in meters per second. At follow-up, mean change and proportion
experiencing meaningful decline defined as reduction in gait speed of 4% annually on
average22 were evaluated. For persons alive at Year 4 who did not have a clinic but had a
home visit, timed gait over 4 meters was used. Self-report of severe walking difficulty (a lot
of difficulty or inability to walk ¼ mile) was considered indicative of decline among those
with phone contact only. Anyone requiring a walking aid was also considered to have
declined.
Cardiorespiratory fitness was determined from performance on the Long Distance Corridor
Walk (LDCW), a two-stage, self-paced endurance walk test performed over a 20-m course.
23, 24 Persons with any of the following electrocardiogram abnormalities: Wolff-Parkinson-
White or ventricular pre-excitation, idioventricular rhythm, ventricular tachycardia, third
degree or complete A–V block, evidence of acute injury or ischemia or marked T-wave
abnormality; systolic or diastolic blood pressure exceeding 199 mmHg or 109 mmHg,
respectively; or heart rate below 40 or above 110 beats per minute were excluded from
testing. Participants reporting a myocardial infarction, angioplasty, or heart surgery in the
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prior 3 months or experiencing new or worsening symptoms of chest pain, shortness of
breath, fainting or angina were also excluded.
Heart rate was monitored during testing (Polar Pacer, Model 61190, Polar Electro, Oy,
Finland) and participants were stopped if their heart rate exceeded 135 beats per minute (85
to 95% of the age-predicted maximum heart rate25) or they experienced debilitating pain,
shortness of breath, syncope or excessive fatigue. Meeting exclusion criteria, inability to
complete the test, time needed to complete 400 meters and fitness categories were examined.
At follow-up, only those persons who completed the LDCW in Year 2 were evaluated for
decline defined as exclusion from or inability to complete the LDCW in Year 4 or needing
8% more time to walk 400 meters.
Covariates—Covariates encompass socio-demographic factors including age, self-
designated white or black race, sex, and study site; self-reported physician diagnosed thyroid
disease obtained from the Year 1 interview and behavioral factors known to impact walking
ability in late life including walking related physical activity, measured weight, smoking
status (current and late-life quitters versus never and former smokers who quit prior to age
50), and self-perceived health status. Use of thyroid hormone medications for study
exclusion in Year 2 and to adjust for treatment in Year 3 was determined from an inventory
of all medications taken within the past two weeks coded using the Iowa Drug Information
System by trained interviews from the containers participants brought to their clinic visit.
Statistical Analyses
For analysis, the population was divided into three groups – euthyroid, mild subclinical
hypothyroid and moderate subclinical hypothyroid – as described above. Participant
characteristics within thyroid function group were compared using a chi-square or t test as
appropriate. Baseline (Year 2) differences in the walking ability parameters across the three
thyroid function categories were evaluated using least squares means adjusted initially for
age and sex and then for race, study site, smoking, reported thyroid disease, body weight,
self-rated health, walking behavior and any significant interactions between thyroid function
category and sex and race. Differences in usual and rapid gait speed and walking index score
over nine categories TSH were evaluated using least square means adjusted for age and sex.
In the longitudinal analyses conducted two years later, for each mobility parameter we
compared the mean change and percent decline between Year 2 and Year 4, and mean value
in Year 4 across categories of thyroid function assessed in Year 2. In the analyses of mean
change in addition to age and sex, Year 2 status of the outcome of interest was included in
the modeling as was new use of thyroid agonists over the follow-up period using medication
data obtained in Year 3. These longitudinal analyses were limited to individuals with
complete follow-up data. All analyses used SAS version 9.1.3 (Cary, NC).
RESULTS
Concurrent Associations
The 2290 participants examined had a mean age of 74.6 years and 10.6% of men and 12.3%
of women met criteria for subclinical hypothyroidism. With the exception of a higher
percentage of blacks in the euthyroid group and greater walking activity in the mild
subclinical hypothyroid group, participant characteristics did not differ across categories of
thyroid function (Table 1). Mobility status, however, was somewhat better in the mild
subclinical hypothyroid group, who in age- and sex-adjusted analyses demonstrated faster
mean usual and rapid gait speed, better cardio-respiratory fitness as indicated by a higher
percentage having good fitness and an overall faster mean 400-m walk time in persons
completing the test, and better perceived walking ability, evidenced by a higher percentage
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who reported walking for 1 mile is very easy and a higher mean walking ability score (Table
2a). The extent of differences observed for usual and rapid gait speed of .05 m/s and .10 m/s
are considered clinically meaningful.22 The mobility status of persons with moderate
subclinical hypothyroidism was generally no worse than the euthyroid group with the
exception of having higher rates of exclusion from the LDCW and reported walking
difficulty.
The mobility advantage of the mild subclinical hypothyroid over the euthyroid group with
respect to usual and rapid gait speed and cardiorespiratory fitness remained after adjustment
for race, study site, smoking status, body weight, reported thyroid disease diagnosis, self-
rated health, walking behavior and the interaction between race and thyroid function (Table
2b). After adjustment, persons with moderate subclinical hypothyroidism continued to show
a higher prevalence of mobility deficits with respect to meeting exclusion criteria for
endurance walk testing and reported walking difficulty. There was no interaction between
sex and thyroid function group and any mobility parameter (p=.13 – .73), but significant
interactions between race and thyroid function with respect to usual walking speed (p=.058)
and 400-m walk time (p=.010).
Figure 1 provides age and sex adjusted means for usual and rapid gait speed across nine
categories of TSH. Both usual and rapid gait speed increased with TSH level up to
approximately 7.45 mU/L with the zenith occurring at the TSH category ranging from 6.45
to 7.45 mU/L. Mean usual and rapid gait speed at this level were statistically different from
the first four categories with TSH levels ranging from 0.45 to 4.45 mU/L (p<.001 to p=.
044). For raid gait speed, categories 3 through 6 (2.45–6.45 mU/L) were also statistically
different from categories 1 and 2 (0.45–2.45 mU/L; p<.001 to p=.016), supporting a mild
protective association between mild subclinical hypothyroidism and mobility defined by gait
speed. Analysis of walking index score showed no association.
Prospective Associations
Two years later, at the Year 4 visit, of the 2290 individuals included in the concurrent
analyses, 102 had died, 4 withdrew from study and 46 had a missed visit and therefore
unknown mobility status leaving 2138 available for evaluation. Neither mortality nor visit
status varied by thyroid function (p>.6). Decline in usual and rapid gait speed, defined as
newly developed inability to walk at least 4 meters without a walking aid or a reduction of
8% or more in speed,22 occurred overall in 28.2% and 35.9%, respectively and did not vary
by thyroid function (see Table 3a). Mean percent decline in the euthyroid and mild and
moderate subclinical hypothyroid groups for usual gait speed was 3.9, 4.6 and 3.9
respectively and 7.3, 8.0 and 8.3 for rapid gait speed which also did not vary by thyroid
function in adjusted analyses. Among the 1652 participants completing the LDCW in Year
2, 1444 (87.4%) had a Year 4 clinic visit, the likelihood of which did not vary by thyroid
function (p>.8). Just over 25% evidenced decline in cardio-respiratory fitness (exclusion
from or inability to complete the LDCW or 8% slower time to walk 400 meters) which also
did not vary by thyroid function. Lastly, overall, 34% experienced at least a one point
decrease in their walking ability score, which did not differ by thyroid status.
Even though the likelihood of decline was uniform across categories of thyroid function,
persons with mild subclinical hypothyroidism retained a slight functional advantage relative
to the euthyroid group two years later with respect to usual and rapid gait speed, time to
walk 400 meters among those completing the test and reported function – percent
responding that walking 1 mile is very easy and mean walking ability score (see Table 3b).
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DISCUSSION
Study findings indicate that generally well-functioning persons in their seventies with a TSH
level falling in the mild subclinical hypothyroidism range (4.5–7.0 mU/L) do not have
poorer functional mobility than their euthyroid counterparts. On the contrary, on the most
demanding mobility parameters examined, these individuals appear to have a slight mobility
advantage. Although persons in the moderate subclinical range (7.0–20.0 mU/L) had higher
rates of perceived walking difficulty and contraindication to endurance activity in
comparison to those in the euthyroid range, they demonstrated similar function on other
mobility parameters. An examination of gait speed by finer categorizations of TSH level
indicates that functional reserve increases with increasing TSH until 7.45 mU/L when it
begins to decline. Remarkably, even in persons with TSH levels up to 10 mU/L rapid gait
speed was statistically significantly faster than persons at the lowest level of TSH (.45–1.45
mU/L; all p<.001 except the second category where p=.011).
Few studies have examined functional status by thyroid function in older individuals. The
Leiden 85-Plus Study18 found no association between TSH level and prevalence of
disability in basic and instrument activities of daily living (ADL), however, those with
higher TSH levels had less decline in instrumental ADL over four years. Even though
measures of functional mobility are not directly comparable to ADL competence, findings
from the current study are generally consistent with this work; in that, thyroid function was
not found associated with functional deficits and when differences emerged persons with
mildly elevated TSH levels demonstrated a functional advantage. The findings reported
herein provide further support for a positive association between TSH level and functional
independence and extends the association to a slightly younger group. Another study26
involving community-resident men aged 73 years and older in The Netherlands found
greater grip strength and better lower-extremity performance in persons with higher FT4
levels. The association between TSH level and physical performance was not reported.
Even though findings indicate that older adults with subclinical hypothyroidism function as
well as if not better than those with normal thyroid function, it is not known whether
individuals with subclinical hypothyroidism who initiate treatment would experience
improved or less decline in mobility. Based on medication data collected in Year 3, just
under half (31 / 47.7%) of the 65 individuals with moderate subclinical hypothyroidism in
Year 2 who were alive in Year 4 with complete follow-up data began new use of thyroid
agonists. Examining gait speed decline, we found no difference between those who did and
did not initiate treatment (27.7 vs. 18.9% p=.412 for usual and 44.4 vs. 24.2% p=.096 for
rapid gait); however, the sample size is too small to make a definitive judgment. If anything,
those initiating treatment tended to exhibit higher rates of decline.
It remains unclear if a mildly elevated TSH level directly contributes to better mobility
status or reflects an underlying positive adaptation that fosters robust health. Recent
observations of a right shift in the distribution of TSH with age1 and the apparent protective
association with mortality in advanced age,18 have led to speculation that increased TSH
secretion may be an adaptive response to an accumulation of thyroid antibodies that
frequently occurs with age16 and thus may be a marker of pituitary resiliency and health.
Others have suggested that a lower metabolic rate may protect against excessive catabolism.
26
An important study limitation concerns incomplete assessment of thyroid function. As in
most other observational cohort studies, 5, 8, 10 TSH level was measured on a single
occasion. Given that acute stress, high physical activity and several pharmacologic agents
can affect TSH level, a single high reading may represent a transient benign elevation.14, 16
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FT4 was not measured in participants with a TSH between 4.5 and 6.9 mU/L, therefore
some persons with overt hypothyroidism may have been included with the mild subclinical
hypothyroidism group, which would tend to bias the findings towards poorer mobility
function and underestimate any mobility advantage. In as much as casual assessment of TSH
undertaken in a routine medical visit may serve as the basis for follow-up testing and
possible treatment, the findings reported here suggest that for individuals in their seventies, a
mildly elevated TSH level is no cause for concern. The small number of participants in the
moderate subclinical hypothyroid group constitutes another limitation and thus findings of
no difference between groups should be treated with caution.
Even though few studies have considered new treatment in examining differential outcomes
by thyroid function over time,26 assessment of medication use over the follow-up period was
limited to Year 3 only. Since participants received a report of their TSH levels after their
Year 2 clinic visit, we would expect most new use to occur in Year 3 and as reported above
new use was not found to impact rate of mobility decline. Therefore the lack of medication
data from Year 4 does not appear to present a major shortcoming.
In summary, in generally well-functioning community resident persons in their seventies,
mildly elevated TSH levels do not appear to indicate or confer health risks as reflected by
multiple parameters of functional mobility. Despite the Institute of Medicine’s
recommendation against routine TSH screening and thus treatment of asymptomatic
subclinical hypothyroidism,26 controversy remains as to whether and when treatment should
be initiated even in older adults.27 We believe the findings reported herein provide
supportive evidence that mild to moderate elevations in TSH with normal FT4 pose little
threat to the health and functioning of older adults. A better understanding of the meaning of
the age-related increase in TSH level and its potential benefit warrants further study and
consideration.
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Figure 1.
Mean usual and rapid gait speed (m/s) by TSH level
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Table 1
Baseline Characteristics by Thyroid Status in the Health ABC Study
TSH, mU/L
Characteristics   0.45 – 4.49   4.50 – 6.99   7.00 – 20.0a
N = 2290, No.     2028     191     71
Age, mean (SD), y 74.6 (2.9) 75.0 (2.8) 75.0 (2.5)
Female, % 47.0 50.8 52.1
Black, % 41.5 23.6 22.5
Memphis site, % 50.1 52.4 45.1
Current or recent smoker, % 29.0 23.0 33.8
Reported diagnosis of hypothyroidism   2.5   4.7   2.8
Reported diagnosis of hyperthyroidism   2.5   2.1   4.2
Very good to excellent self-rated health, % 47.5 48.2 48.6
Fair to poor self-rated health, % 14.4 15.7 14.3
Weight, mean (SD), kg 75.7 (15.1) 73.2 (14.6) 75.2 (15.9)
Walks less than 30 minutes/week, % 44.2 35.6 39.4
Abbreviations: Health ABC, Health, Aging and Body Composition; TSH, thyroid-stimulating hormone
a
With normal free thyroxine levels (0.8 to 1.8 ng/dL for assay used)
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Table 2
Table 2a. Baseline Mobility Parametersa by Thyroid Status
TSH, mU/L
Walking Ability Parameters   0.45 – 4.49   4.50 – 6.99   7.0 – 20.0b
N = 2290, No.     2028     191     71
Usual gait speed, mean (SD), m/s 1.15 (.20) 1.20 (.22)c 1.17 (.23)
Rapid gait speed, mean (SD), m/s 1.56 (.31) 1.65 (.33)c 1.59 (.32)
Excluded from LDCW, % 13.3 10.8 22.3d
Incomplete LDCW, % 17.0 14.4 14.5
400 meter time, mean (SD), s 321.7 311.1d 314.8
Good cardiorespiratory fitness, % 28.0 39.2c 28.3
Reports difficulty walking ¼ mile, % 16.2 14.7 26.2d
Reports walking 1 mile is very easy, % 36.5 44.7d 36.1
Walking ability index score, mean (SD) 6.74 7.08 6.23
Table 2b. Baseline Mobility Parameterse by Thyroid Status - Fully Adjusted
TSH, mU/L
Walking Ability Parameters   0.45 – 4.49   4.50 – 6.99   7.0 – 20.0b
N = 2290, No.     2028     191     71
Usual gait speed, mean (SD), m/s 1.15 (.20) 1.18 (.22)d 1.17 (.23)
Rapid gait speed, mean (SD), m/s 1.56 (.31) 1.62 (.33)f 1.57 (.32)
Excluded from LDCW, % 13.1 12.3 23.9d
Incomplete LDCW, % 16.8 16.7 16.1
400 meter time, mean (SD), s 321.6 312.5d 314.6
Good cardiorespiratory fitness, % 28.3 36.2d 28.6
Reports difficulty walking ¼ mile, % 16.0 17.0 26.8d
Reports walking 1 mile is very easy, % 37.0 40.0 34.0
Walking ability index score, mean (SD) 6.76 6.87 6.16d
Abbreviations: TSH, thyroid-stimulating hormone; LDCW, Long Distance Corridor Walk
a
Adjusted for age and sex
b
With normal free thyroxine levels (0.8 to 1.8 ng/dL for assay used)
c
P<.001 for comparison with euthyroid category
d
P<.05 for comparison with euthyroid category
e
Adjusted for age, sex, race, study site, smoking, reported thyroid disease, body weight, self-rated health, walking behavior, and the interaction
between race and thyroid function
f
P<.01 for comparison with euthyroid category
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Table 3
Table 3a. Prevalence of Decline in Walking Ability after Two Yearsa by Baseline Thyroid Status
TSH, mU/L
Walking Ability Parameters 0.45 – 4.49 4.50 – 6.99 7.0 – 20.0b
N = 2138, No. 1897 176 65
Declined in usual gait speed, % 28.1 31.3 22.2
Declined in rapid gait speed, % 36.4 31.5 33.0
Declined in cardiorespiratory fitnessc, % 25.4 23.5 25.2
Declined in walking ability score, % 34.1 29.9 41.0
Table 3b. Walking Ability after Two Yearsd by Baseline Thyroid Status
TSH, mU/L
Walking Ability Parameters 0.45 – 4.49 4.50 – 6.99 7.0 – 20.0b
N = 2138, No. 1897 176 65
Usual gait speed in year 4, mean, s 1.10 1.15e 1.14
Rapid gait speed in year 4, mean, s 1.44 1.55f 1.50
Good cardiorespiratory fitnessg, % 23.0 31.6e 27.0
400 meter time in year 4, mean, s 328.5 312.3f 316.3
Reports difficulty walking ¼ mile, % 21.0 17.5 25.2
Reports walking 1 mile is very easy, % 36.9 46.4e 28.9
Walking ability score in year 4, mean 6.46 6.90e 6.10
Abbreviations: TSH, thyroid-stimulating hormone
a
Adjusted for age, sex, baseline walking ability and use of thyroid agonists in Year 3
b
With normal free thyroxine levels (0.8 to 1.8 ng/dL for assay used)
c
Among the 1444 participants completing the LDCW in Year 2 having a Year 4 clinic visit
d
Adjusted for age, sex and use of thyroid agonists in year 3.
e
P<.05 for comparison with euthyroid category
f
P<.01 for comparison with euthyroid category
g
Among the 1959 participants having a Year 4 clinic visit
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